Nick Bird, IT Consultant at NJB Consulting, shared on LinkedIn:
“In 2026, paediatric oncology must build more coordinated and fit-for-purpose drug development pathways – designed to lead to approvals of, and access to, better drugs to treat childhood cancers.
In our new article in The Lancet Child and Adolescent Health, co-authored by advocates and regulators, we call on academia, industry, regulators, advocates and funders to align around a new strategy: using a Target Product Profile (TPP) from the outset to guide the development of new products.
Europe’s incoming Pharmaceutical Legislation reform is the opportunity to make this strategic shift – one that could drive real improvements in both survival and quality of survival for children with cancer.
Thanks to co-authors Nicole Scobie, Dr. Victoria Buenger, Martha Donoghue, Dominik Karres.”
Title: Calling for a strategic shift in drug development for childhood cancers
Authors: Nicholas Birda, Nicole Scobieb, Vickie Buengerc, Martha Donoghued, Dominik Karres
Other articles about Paediatric Cancer on OncoDaily.
